GLAXOSMITHKLINE PRODUCT ADVISORY

27 October 2025

Dear Pharmacists and Respiratory Therapists,

GlaxoSmithKline Inc.
100 Milverton Drive
Suite 800
Mississauga, ON
Canada 15R 4H1

Tel: 905 819 3000 www.gsk.ca

VENTOLIN HFA (salbutamol pressurised inhalation, suspension) – reinforcing information regarding the number of doses available in the metered dose inhaler

GlaxoSmithKline Inc would like to reiterate important information concerning VENTOLIN HFA.

The inhaler contains enough salbutamol for 200 actuations (puffs) only. After 200 actuations (puffs), the inhaler can continue to spray but without the prescribed dose of salbutamol.

Key Messages

- Methods such as shaking, weighing or submerging inhalers are not accurate for determining that an inhaler is empty of the prescribed dose of salbutamol.
- Accordingly, maintaining a record of the number of actuations (puffs) used should be considered to avoid the inadvertent use of an empty inhaler.
- Patients keeping a back-up inhaler could be considered. If the patient has more than one inhaler, it is recommended to keep track of each inhaler separately.

Action Required by Pharmacists and Respiratory Therapists

Pharmacists and Respiratory Therapists should reinforce this information with their patients.

Further Information

This letter reinforces updates made to the Product Monograph for VENTOLIN HFA.

The Product Monograph for VENTOLIN HFA can be accessed at GSK.ca.

To report an adverse event, please go to gsk.public.reportum.com or call GSK Canada at 1-800-387-7374.

Alternatively, adverse events may be reported to Health Canada by calling 1-866-234-2345 or visiting canada.ca/drug-device-reporting.

Contact(s) for Further Information or Questions

For all questions, please contact: Medical Information at GlaxoSmithKline Canada: 1-800-387-7374

Michelle Horn

VP and Country Medical Director, Canada

GlaxoSmithKline Inc.